Adimab launches four novel antibody-based technologies

By The Science Advisory Board staff writers

January 28, 2022 -- Adimab has expanded its proprietary technologies available for use in drug development. The expansion will aid in the development of antibody and multispecific therapeutic modalities, the firm said.

These technologies are the result of a collaborative effort between Adimab's computational biology team in Palo Alto, CA, and its antibody engineering team in Lebanon, NH, to provide Adimab's partners with end-to-end solutions for therapeutic antibodies across multiple formats.

Among the four proprietary technologies Adimab has released, the first is a set of first-generation, heavy chain-only antibody (HCAb) libraries designed to meet the growing demand for single-domain antibodies. The HCAb libraries aim to minimize developability risk while ensuring high sequence diversity and broad epitope coverage.

Utilizing the Adimab HCAb libraries follows the same efficient workflows and timelines of the company's standard immunoglobulin G (IgG) discovery and optimization process. In addition, Adimab said it has employed both extensive structural modeling and directed protein evolution to derive novel heterodimerization solutions both at the heavy chain/light chain interface as well as the heavy chain interface in the CH3 domain. This readily allows for the formation of an IgGlike bispecific from any two antibodies, or the flexibility to generate other multispecific therapeutic molecules.

Adimab has also developed constant region mutations for Fc-silencing. Adimab's Fc-silencing mutations allow its partners to exclusively focus the therapeutic impact of their antibody on the variable domain target specificity while maintaining favorable developability properties expected of full-length antibodies.

Lastly, Adimab has developed specific Fc engineering solutions and screening assays that enable the half-life extension of therapeutic antibodies and multispecific molecules in humans. Recent data generated in a phase I clinical trial demonstrated an IgG half-life exceeding three months. Adimab has filed multiple patents on these technologies.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.